GLYCIPHAGE G® Tablets
Composition:
GLYCIPHAGE-G® 0.5:
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P. (in Prolonged-release form).…………………………………………………………. 500 mg
- Glimepiride I.P. …………………………….……….. 0.5 mg
Colour: Brilliant Blue FCF (C.I. No. 42090)
GLYCIPHAGE-G1®:
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P. (In sustained-release form) …..…………………………….…….………………………………………………. 500 mg
- Glimepiride I.P. ……….……………………………………………. 1 mg
Colour: Red Oxide of Iron
GLYCIPHAGE-G2®:
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P. (In sustained-release form) …...…………………………………………………………………………………… 500 mg
- Glimepiride I.P. ……….……………………………………………… 2 mg
Colours: Yellow Oxide of Iron, Titanium Dioxide I.P.
GLYCIPHAGE-G1 FORTE®:
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P(in Prolonged -release form) …..…………………………………………………………………………... 1000 mg
Glimepiride I.P. …………………………………………….. 1 mg
GLYCIPHAGE-G2 FORTE®:
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P(in Prolonged -release form) …...……….……………………………………………………. 1000 mg
Glimepiride I.P. ……….…………………… 2 mg
Description
- GLYCIPHAGE-G tablets contain two oral anti-hyperglycaemic drugs, Glimepiride and prolonged-release Metformin hydrochloride, used in the management of Type 2 Diabetes.
- Metformin hydrochloride improves glucose tolerance by decreasing hepatic glucose production, decreasing gluconeogenesis, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization.
- The action of Glimepiride in GLYCIPHAGE-G is mainly attributed to its initial activity of stimulation of the beta cell for insulin secretion; however, it has also an insulin-mimetic effect in peripheral tissues, possibly mediated by GLUT-4 recruitment. The extra-pancreatic effects may explain the lesser degree of stimulated hyperinsulinemia.
- Hence, the combination of Glimepiride and Metformin hydrochloride sustained-release complement each other and provides better glycaemic control in the management of Type 2 Diabetes.
Indications
- GLYCIPHAGE-G® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus who are already treated with a combination of Glimepiride and Metformin, given separately, or whose diabetes is not adequately controlled with Metformin alone, or for those patients who have initially responded to Glimepiride alone and require additional glycaemic control.
×
![]()